Seoulin Bioscience Co.Ltd (038070) — Cash Flow Quality Index
Seoulin Bioscience Co.Ltd (038070) has a Cash Flow Quality Index of 3.62x as of September 2025. Operating cash flow of ₩2.78 Billion exceeds net income of ₩766.93 Million, indicating high earnings quality where cash backs reported profits. Explore 038070 cash generation efficiency to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Seoulin Bioscience Co.Ltd Cash Flow Quality Index (2013–2025)
Historical Cash Flow Quality Index for Seoulin Bioscience Co.Ltd across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 038070 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Seoulin Bioscience Co.Ltd (2013–2025)
Year-by-year earnings quality comparison for Seoulin Bioscience Co.Ltd. For live market cap and the full company financial profile, see Seoulin Bioscience Co.Ltd (038070) total market value.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 6.50x | ₩4.76 Billion | ₩731.98 Million | ▲ +542.8% |
| 2024 | -1.47x | ₩-4.61 Billion | ₩3.14 Billion | ▼ -221.7% |
| 2022 | -0.46x | ₩-4.36 Billion | ₩9.54 Billion | ▼ -179.8% |
| 2021 | 0.57x | ₩8.92 Billion | ₩15.59 Billion | ▼ -24.0% |
| 2020 | 0.75x | ₩3.68 Billion | ₩4.89 Billion | ▼ -8.6% |
| 2019 | 0.82x | ₩7.32 Billion | ₩8.88 Billion | ▼ -48.2% |
| 2018 | 1.59x | ₩4.17 Billion | ₩2.62 Billion | ▲ +151.9% |
| 2017 | 0.63x | ₩1.30 Billion | ₩2.06 Billion | ▼ -4.7% |
| 2016 | 0.66x | ₩2.76 Billion | ₩4.16 Billion | ▼ -70.6% |
| 2015 | 2.26x | ₩4.12 Billion | ₩1.83 Billion | ▲ +119.7% |
| 2014 | 1.03x | ₩2.74 Billion | ₩2.67 Billion | ▼ -13.5% |
| 2013 | 1.19x | ₩4.94 Billion | ₩4.16 Billion | — |